NON-FINAL REJECTION
Receipt is acknowledged of Applicants' Amendments and Remarks, filed Jul. 6, 2026.
Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The rejections and/or objections set forth below are either maintained or newly applied, and constitute the complete set presently applied to the instant claims.
STATUS OF THE CLAIMS
Claims 1-17, 25, and 34 have been canceled.
Claims 18, 21, 24, 26, 30, 31, and 33 have been amended and incorporate no new matter.
New claims 35-38 have been added.
Thus, claims 18-24, 26-33, and 35-38 now represent all claims currently pending and under consideration.
INFORMATION DISCLOSURE STATEMENT
No new Information Disclosure Statements (IDS) have been submitted.
RESPONSE TO AMENDMENTS & ARGUMENTS
Applicant’s amendments and arguments filed Jul. 6, 2026 overcome the rejections set forth in the non-final action dated Mar. 6, 2026. However, upon further consideration, a new ground of rejection is set forth below.
NEW REJECTIONS
Claim Rejections - 35 U.S.C. § 112(a) – Scope of Enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 18-24, 26, 30-33, 35, and 36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for methods of treating polycystic kidney disease (PKD) and pancreatic cysts associated with autosomal-dominant PKD, does not reasonably provide enablement for methods of treating any ciliopathy. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.
MPEP § 2164.01(a), citing In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), sets out the factors to determine whether experimentation is undue. These factors are applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108,427 F.2d 833,839, 166 USPQ 18, 24 (1970). An analysis of the Wands factors follows.
(A) The breadth of the claims. Independent claim 18 is drawn to a method of treating any ciliopathy by administering to a patient in need thereof a therapeutically effective amount of a TRPML ion channel activator (agonist) of Formula (III):
PNG
media_image1.png
159
144
media_image1.png
Greyscale
.
The disclosure defines "ciliopathies" to include polycystic kidney disease, pancreatic cysts in polycystic kidney disease, Bardet-Biedl syndrome, nephronophthisis, Joubert Syndrome, Mecke-Gruber Syndrome, oral-facial-digital syndrome, Senior Loken Syndrome, Birt-Hogg-Dube syndrome, Leber's congenital amaurosis, Alstrom syndrome, Jeune asphyxiating thoracic dystrophy. Ellis van Creveld syndrome, Sensenbrenner syndrome, primary ciliary dyskinesia (para. [0109]), autosomal dominant polycystic kidney disease, and autosomal recessive polycystic kidney disease (paras. [0039]-[0040]), as recited by claim 26.
Thus, the claim scope is extremely broad, both in the breadth of compounds of formula (III), and in the breadth of the patient population treated, which encompasses ciliopathies which differ in causative genes, primary organ involvement, age of onset, and clinical course.
(B) The nature of the invention. The claims are directed to treatment of a broad range of rare genetic diseases with a small-molecule ion-channel activator. Such methods require not only identification of an active compound, but also a demonstration that modulation of the molecular target produces a therapeutic effect in the relevant tissue and disease context.
(C) The state of the prior art. Ciliopathies are a recognized but heterogeneous family of disorders linked by defective cilia. PKD is the most common, whereas the other claimed ciliopathies are rare and mechanistically diverse. Further, the prior art does not establish that TRPML activation is a general, predictive therapy across any and all ciliopathies.
For example, Liang (WO 2018/005713, of record) discloses structurally similar benzenesulfonamides as TRPML modulators useful for treating disorders related to TRPML activities, such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, ROS or oxidative stress related diseases, and aging (claims 10-18). None of these diseases appear to overlap with the claimed ciliopathies.
Liang (WO2018/208630, of record) further discloses structurally similar arylsulfonamides as TRPML modulators useful for treating acid-related disorders, gastric disorders, and cancer, and for modulating tubulovesicle and lysosome functions (claims 10-20). None of these diseases appear to overlap with the claimed ciliopathies.
Leit De Moradei et al. (WO 2020/097408, of record) disclose structurally similar benzenesulfonamides useful in methods of treating, e.g., symptoms of Bardet-Biedl syndrome (claim 23), as recited by claim 26. However, the compounds are not explicitly disclosed as modulators of TRPML, nor is the treatment of any other ciliopathies disclosed.
Stallone et al. (of record) report a clinical trial to evaluate low-dose and high-dose rapamycin in the treatment of autosomal dominant polycystic kidney disease (ADPKD) (abstract). As evidenced by Zhang et al. (of record), rapamycin binds directly to TRPML1, and is a specific and robust activator of TRPML1, independent of mTOR (abstract; results). Stallone et al. found that, although rapamycin treatment is relatively safe, it does not significantly affect the progression of ADPKD (conclusion). While the higher rapamycin dose reduced the increase in total kidney volume and the decline in renal function, there is no evidence that this is due to rapamycin's activity as a TRPML ion channel activator.
Similarly, Wüthrich et al. (of record) report that clinical trials examining the mTOR inhibitors sirolimus (a.k.a. rapamycin) and everolimus in the treatment of ADPKD failed to show a beneficial effect on change in kidney volume and renal function (p. 1088), or a significant improvement in cyst growth and GFR (glomerular filtration rate) decline (p. 1091).
Thus, there is scant evidence in the prior art demonstrating the treatment of a ciliopathy by administering a TRPML ion channel activator.
(D) The level of one of ordinary skill & the level of predictability in the art. One of ordinary skill in the art would be a scientist or a clinician with advanced training in renal or ciliary biology, ion-channel pharmacology, and translational development of treatments for rare genetic diseases, familiar with organoid and knockout-cell assays. Nonetheless, translational medicine is highly unpredictable. Efficacy of a lysosomal-channel activator in an in vitro PKD1 cyst model does not reliably predict efficacy against ciliopathies other than polycystic kidney disease. Different ciliopathies involve different cell types, ciliary proteins, and downstream pathways. Small molecule translation from organoid cyst size reduction to human therapeutic benefit is uncertain even for PKD, and far less predictable for other, unrelated ciliopathies.
(E) The amount of direction provided by the inventor. The specification provides a general mechanistic rationale for treating ciliopathies: TRPML activation → lysosomal/ autophagic clearance → benefit in ciliopathies. However, the disclosure fails to provide disease-specific models, dosing guidance, tissue-targeting strategies, or data for any indication other than the PKD organoid assay and an NPC lipid assay. No guidance is given as to how a skilled artisan would confirm activity against retinal, neurodevelopmental, skeletal, or motile-cilia disorders.
(F) The existence of working examples. Twenty-four of the 26 examples set forth in the specification relate to synthesis of compounds of formula (III). There is no disclosure of treating any ciliopathy by administering a TRPML ion channel activator in vivo; and only two examples demonstrating the activity of the claimed compounds in vitro.
Example 25 and Figs. 1-3 describe the effect of four TRPML1 activators on glycophosphingolipid levels and cyst areas using genetic models of disease, which reasonably correlates to one recited indication (PKD1 organoid cyst swelling).
Example 26 describes TRPML-1, TRPML-2, and TRPML-3 fluorescent assays in cell culture, which does not model a claimed ciliopathy.
No working examples are provided for the other claimed ciliopathies; and the specification presents no in vivo efficacy data in any ciliopathy model.
(G) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. A skilled artisan would need to obtain or generate appropriate cellular or animal models for ciliopathies other than PKD; test multiple compounds against broad dosage ranges, evaluate relevant tissue-specific readouts; and determine whether any observed in vitro activity translates in vivo, which goes far beyond routine experimentation. Given the breadth of the claims, the lack of guidance and working examples for ciliopathies other than polycystic kidney disease, and the high unpredictability in the art, one of ordinary skill in the art could not practice the full scope of the claimed invention without undue experimentation.
Allowable Subject Matter
Claims 27-29 and 37-38 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
CONCLUSION
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARA E. TOWNSLEY whose telephone number is 571-270-7672. The examiner can normally be reached on Mon-Fri from 10:00 am to 6:00 pm (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeff S. Lundgren, can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SARA E. TOWNSLEY/Examiner, Art Unit 1629